Welcome to the Content Library for the TGFβ for Immuno-Oncology Drug Development Summit
If you have anything you would like us to share in the content library, please contact us at firstname.lastname@example.org
AN EXCLUSIVE INTERVIEW WITH:
Chief Executive Officer
"TGF-β is arguably one of the most immunosuppressive cytokines in virtually all solid tumors. In addition, TGF-β drives resistance to immune checkpoint therapies in multiple solid tumors, positioning it as a key pathway to target in order to improve patient outcome."
AN EXCLUSIVE INDUSTRY SURVEY:
Take a look at our industry-wide survey results to get a better understanding of the current industry landscape and the challenges faced with the development of TGF-beta for IO therapeutics.